CCL26 and primary cutaneous T-cell non-Hodgkin lymphoma: CCL26 is thought to reflect a Th2-skewed cytokine milieu in CTCL lesions, potentially reinforcing Th2-associated inflammation and thereby correlating with disease progression and poor prognosis [56,61,62].